Business
Novartis to Acquire Excellergy for Up to $2 Billion to Enhance Food Allergy Drug Offerings
Novartis has announced its intention to purchase Excellergy, a US-based biotechnology firm, in a deal potentially worth $2 billion. This acquisition aims to strengthen its immunology pipeline and expand its operations in the United States.